LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

Elanco Animal Health Inc

Open

BrancheGesundheitswesen

12.92 0.16

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

12.78

Max

12.99

Schlüsselkennzahlen

By Trading Economics

Einkommen

75M

67M

Verkäufe

173M

1.2B

KGV

Branchendurchschnitt

17.093

56.602

EPS

0.37

Gewinnspanne

5.616

Angestellte

9,000

EBITDA

86M

261M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+13.06% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.6B

6.4B

Vorheriger Eröffnungskurs

12.76

Vorheriger Schlusskurs

12.92

Nachrichtenstimmung

By Acuity

50%

50%

173 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Elanco Animal Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Mai 2025, 11:29 UTC

Akquisitionen, Fusionen, Übernahmen

Elanco Sells Non-Core Asset to Blackstone for $295 Million

27. Juni 2024, 14:34 UTC

Wichtige Markttreiber

Elanco Shares Retreat Over Zenrelia Warning Label Concerns

5. Mai 2025, 11:14 UTC

Akquisitionen, Fusionen, Übernahmen

Elanco Sells Non-Core Asset to Blackstone for $295 Mln

5. Mai 2025, 10:50 UTC

Akquisitionen, Fusionen, Übernahmen

Elanco Animal Health: Monetization of This Non-Core Asset Will Be Used to Accelerate Debt Reduction >ELAN

5. Mai 2025, 10:49 UTC

Akquisitionen, Fusionen, Übernahmen

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone for $295M

9. Juli 2024, 12:30 UTC

Akquisitionen, Fusionen, Übernahmen

Merck Animal Health Completes Acquisition Of Elanco's Aqua Business >MRK

9. Juli 2024, 12:29 UTC

Akquisitionen, Fusionen, Übernahmen

Elanco Animal Health Sees Ending 2024 With Net Debt to Adjusted Ebitda in Mid-4x Range >ELAN

9. Juli 2024, 12:28 UTC

Akquisitionen, Fusionen, Übernahmen

Elanco Animal Health: $1.05B-$1.1B Net Proceeds Available for Debt Paydown in 3Q >ELAN

9. Juli 2024, 12:28 UTC

Akquisitionen, Fusionen, Übernahmen

Elanco Completes Sale of Aqua Business to Merck >ELAN MRK

Peer-Vergleich

Kursveränderung

Elanco Animal Health Inc Prognose

Kursziel

By TipRanks

13.06% Vorteil

12-Monats-Prognose

Durchschnitt 14.63 USD  13.06%

Hoch 20 USD

Tief 10 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Elanco Animal Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

11 ratings

7

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

9.77 / N/AUnterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Weak Bullish Evidence

Stimmung

By Acuity

173 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Elanco Animal Health Inc

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.